Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States.
|
[11-January-2018] |
LEAWOOD, Kan., Jan. 11, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics (NASDAQ: PETX), today announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union. Galliprant is a new veterinary medicine that will be indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Grapiprant, the active ingredient in Galliprant, is a non-steroidal non-cyclooxygenase inhibiting anti-inflammatory drug. Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States. About Elanco Animal Health About Aratana Therapeutics This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the collaboration between Aratana and Elanco, and reflects Lilly, Elanco’s and Aratana’s current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that the research collaboration will yield successful results, that either company will achieve the anticipated benefits or that the results will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s and Aratana’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission, respectively. Except as required by law, Elanco and Aratana undertakes no duty to update forward-looking statements to reflect events after the date of this release. Media Contacts Karin Gerbens Rachel Reiff View original content with multimedia:http://www.prnewswire.com/news-releases/elanco-aratana-announce-marketing-authorization-of-galliprant-grapiprant-tablets-in-europe-300581366.html SOURCE Aratana Therapeutics | ||
Company Codes: NASDAQ-NMS:PETX, NYSE:LLY |